The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | PACIFIC-BRAZIL: intensified induction chemo-IO in stage III NSCLC
Gerry Hanna, MBBCh, PhD, MRCP, FRCR, FRANZCR, Trinity College Dublin, Dublin, Ireland, explores the Phase II PACIFIC-BRAZIL study (NCT04230408), which assessed the efficacy and safety of an intensified regimen combining induction chemotherapy and durvalumab, followed by concurrent chemoradiotherapy and consolidation durvalumab in stage III non-small cell lung cancer (NSCLC). Results demonstrated improved 12-month progression-free compared to historical controls. Despite promising efficacy, the trial observed significant grade ≥3 treatment-related adverse events, including pneumonitis and infections. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
